Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now full pipeline small index

Radiation Dermatitis: full-pipeline trial registry

2 of 6 indexed Radiation Dermatitis trials are currently recruiting.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Radiation Dermatitis: 6 US clinical trials tracked, 2 recruiting.

Radiation Dermatitis is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Wake Forest University Health Sciences, running 2 of these trials.

Enrollment posture brief

Registry condition radiation-dermatitis

OPEN 2 | RECR 33% | LATE 1 | EARLY 1 | RANK #2866 | SPON 2

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Radiation Dermatitis (this)33%
Open-enrollment share among volume-matched conditions near Radiation Dermatitis

Radiation Dermatitis lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Radiation Dermatitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Radiation Dermatitis is recruiting below its size-band peers.

    2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Radiation Dermatitis research.

    Wake Forest University Health Sciences accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Radiation Dermatitis trials plan to enrol fewer than 100 people.

    Median target enrolment is 34 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.

  4. Radiation Dermatitis research is mostly interventional.

    5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21Phase 31

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 1

Named interventions

Most-linked intervention names on Radiation Dermatitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Mupirocin Ointment Drug
1 trials
Chlorhexidine gluconate solution Drug
1 trials
Routine Skin Care - Commercially Available Agents Other
1 trials
KeraStat Cream Device
1 trials
Aquaphor Gel Other
1 trials
RadiaPlexRx Gel Other
1 trials
3M™ Cavilon™ Advanced Skin Protectant Other
1 trials
Feedback phone interview Other
1 trials

US sites by state

Facility locations filed on Radiation Dermatitis trials. A trial with sites in several states counts in each.

North Carolina 2 trials
Texas 1 trials
New York 1 trials
Minnesota 1 trials
Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Radiation Dermatitis page

6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Radiation Dermatitis condition card totals 6 registered trials; most-linked intervention Mupirocin Ointment; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.